UCB (OTCMKTS:UCBJF) Trading Down 11.9% – Here’s Why

Shares of UCB SA (OTCMKTS:UCBJF) traded down 11.9% during mid-day trading on Friday . The stock traded as low as $260.3250 and last traded at $260.3250. 4 shares were traded during trading, a decline of 99% from the average daily volume of 746 shares. The stock had previously closed at $295.59.

Wall Street Analyst Weigh In

Separately, Piper Sandler reiterated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

UCB Stock Performance

The company’s 50-day moving average is $292.34 and its 200-day moving average is $300.05. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.